Major Shareholder Fairmount Funds Buys $20M in Recent Public Offering, Increasing Stake to 14.04%
VRDN sits 50% above its 52-week low of $12.07.
Summary
Fairmount Funds Management LLC, a 10% owner, invested $20 million in Viridian Therapeutics' recent public offering, increasing its beneficial ownership to 14.04% of outstanding common stock.
Key Events · Ownership and Investor Activity · VRDN
-
Major Shareholder Increases Stake
Fairmount Funds Management LLC, a 10% owner, purchased 1,176,470 shares of common stock for $19,999,990.00.
-
Participation in Public Offering
The shares were acquired on May 11, 2026, as part of an underwritten public offering, priced at $17.00 per share.
-
New Ownership Percentage
Fairmount Funds Management LLC now beneficially owns 17,201,800 shares, representing 14.04% of the company's common stock.
-
60-Day Lock-Up Agreement
The fund entered into a customary 60-day lock-up agreement, restricting sales of shares without underwriter consent.
Analysis · VRDN · Life Sciences
Fairmount Funds Management LLC, a significant institutional investor, purchased nearly $20 million worth of Viridian Therapeutics common stock in the company's recent public offering. This substantial investment, representing over 1% of the company's market capitalization, demonstrates strong conviction from a major shareholder, especially following the recent positive clinical data and capital raise. The purchase was made at $17.00 per share, and Fairmount has agreed to a 60-day lock-up period, further signaling a commitment to their investment.
At the time of this filing, VRDN was trading at $18.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $12.07 to $34.29. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.